![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Lynparza Approved as Maintenance Treatment for Ovarian Cancer
Lynparza Approved as Maintenance Treatment for Ovarian Cancer
The FDA has approved AstraZeneca’s and Merck’s Lynparza (olaparib) in combination with bevacizumab as a maintenance treatment for adults with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.
The approval was based on the results of a phase 3 clinical trial, which showed that the combination reduced the risk of disease progression or death by 67 percent.
Lynparza was previously approved as a maintenance treatment of platinum-sensitive relapsed ovarian cancer.
Upcoming Events
-
21Oct